Project Grant HT9425261E194
Award Date 8/1/26
Completion Date 7/31/29
Dollars Obligated $483K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $559,998 Project Grant on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on therapeutic targeting of RNA processing to enhance anti-melanoma immunotherapy. The two-year project, concluding May 31, 2028, supports investigator-initiated biomedical research designed to advance medical solutions relevant to Service Member...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $1,145,096 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the project "Modeling and Targeting FH-Deficient Renal Cell Carcinoma for Precision Therapy." The award was issued on July 1, 2026, with a completion date of June 30, 2029. This three-year research initiative will be conducted at the Institute's facility in New York, NY....
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $604,902 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The award funds research titled "Modeling and Targeting FH-Deficient Renal Cell Carcinoma for Precision Therapy," which focuses on developing targeted therapeutic approaches for a specific subset of...
- Federal Grant Award Summary Award Details: The Sloan-Kettering Institute for Cancer Research received a $1.39M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 1, 2025, with performance extending through August 31, 2029. The award supports an integrated immunomodulatory analysis of LAG3 (Lymphocyte-Activation Gene 3) inhibition in renal cell carcinoma (RCC), a hypothesis-driven research initiative addressing...
- Federal Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2026. This award supports research investigating the interactions of mitochondrially encoded Complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to advance...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $176,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research to establish a mouse model of myxoid/round cell liposarcoma with endogenous translocations. The award, effective September 1, 2025, through August 31, 2027, funds basic research aimed at advancing understanding of this rare soft tissue sarcoma through the development of a preclinical...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $750,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2026, through April 30, 2029. The award supports research titled "Eliminating TREX1 to Restore Immune Control in Triple-Negative Breast Cancer," which focuses on investigating immunological mechanisms in breast cancer treatment. This research...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $176,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2027. The award funds research exploring a novel antibody-drug conjugate (ADC) strategy designed to block MYC protein production in neuroblastoma (NB), a pediatric cancer of the nervous system. This research...